🇺🇸 Toviaz (Fesoterodine) in United States

34 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 34

Most-reported reactions

1. Drug Ineffective — 10 reports (29.41%)
2. Nausea — 4 reports (11.76%)
3. Vision Blurred — 4 reports (11.76%)
4. Dizziness — 3 reports (8.82%)
5. Pruritus — 3 reports (8.82%)
6. Application Site Erythema — 2 reports (5.88%)
7. Application Site Pain — 2 reports (5.88%)
8. Application Site Pruritus — 2 reports (5.88%)
9. Application Site Vesicles — 2 reports (5.88%)
10. Arthralgia — 2 reports (5.88%)

Source database →

Frequently asked questions

Is Toviaz (Fesoterodine) approved in United States?

Toviaz (Fesoterodine) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Toviaz (Fesoterodine) in United States?

Weill Medical College of Cornell University is the originator. The local marketing authorisation holder may differ — check the official source linked above.